You are here: Industry Insights > LifeArc

News List

Cumulus Neuroscience raises £6m in Dementia Discovery Fund-led financing round pharmatimes
May 07, 2021
Belfast-headquartered Cumulus Neuroscience has raised £6m in a financing round led by the Dementia Discovery Fund, with the funds set to be used to advance its integrated physiological and digital biomarker platform.
UK gene therapy hub network awarded £18m in funding pharmatimes
March 18, 2021
Medical research charity LifeArc and the Medical Research Council (MRC) have announced three investments totalling £18m for the creation of a UK network of gene therapy hubs.
LifeArc provides £5m funding for COVID-19 genomics study pharmatimes
February 19, 2021
LifeArc, a medical research charity, has announced it will provide £5m in funding to support the GenOMICC COVID-19 study, which is aiming to understand the role of genetic risk factors in patient responses to COVID-19.
Metrion, LifeArc Extend Neuroscience Alliance contractpharma
January 19, 2021
Collaboration extended for another 12 months after successfully progressing into late stage hit-to-lead optimization phase.
MRC and LifeArc announce grants for Gene Therapy Innovation Hubs in UK europeanpharmaceuticalreview
May 08, 2020
The UK MRC and LifeArc are making £16 million available as grants to fund the establishment of Gene Therapy Innovation Hubs to improve resources for researchers and manufacturers.
LifeArc, MRC create £16m fund to set up gene therapy hubs pharmatimes
May 06, 2020
The Medical Research Council (MRC) and independent medical research charity LifeArc are streaming £16 million into establishing a network of gene therapy innovation hubs.
LifeArc receives $1.2b in Keytruda royalties pharmatimes
May 28, 2019
UK-based medical research charity LifeArc has received $1.297 billion from CPPIB Credit Europe for a portion of its royalty interest in MSD’s Keytruda (pembrolizumab).
LifeArc licenses lead stage molecules to Daiichi Sankyo biospectrumasia
April 25, 2019
The licensing deal successfully concludes a research collaboration between LifeArc, Oxford University’s Nuffield Department of Clinical Neurosciences and Daiichi Sankyo.
LifeArc inks pain medicine development deal with Uni of Kent pharmatimes
April 24, 2019
LifeArc and the University of Kent have signed a deal to collaborate on an ion channel drug discovery programme.
LifeArc licenses discovery programme to Daiichi Sankyo pharmatimes
April 18, 2019
The deal successfully concludes a research collaboration between LifeArc, Oxford University’s Nuffield Department of ……

Previous page 1 2 Next page